Recent News

• 09.05.2025 - Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year
• 08.21.2025 - Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027
• 08.13.2025 - Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment
• 08.06.2025 - Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments
• 07.31.2025 - Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results
• 07.28.2025 - FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy
• 07.25.2025 - Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS

Recent Filings

• 08.29.2025 - 8-K Current report
• 08.21.2025 - 8-K Current report
• 08.15.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 08.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - 8-K Current report
• 08.13.2025 - 144 Report of proposed sale of securities
• 08.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]